Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study [Short communication]
Abstract:A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated meta-analyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6–0.95).
Document Type: Short Communication
Affiliations: Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Publication date: August 1, 2009
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites